Steris PLC (STE) News
Filter STE News Items
STE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest STE News From Around the Web
Below are the latest news stories about STERIS PLC that investors may wish to consider to help them evaluate STE as an investment opportunity.
STERIS Gains From Expanded Product Offerings Amid Macro IssuesSTE expects bioprocessing revenues to grow in the second half of fiscal 2025. |
Are Investors Undervaluing STERIS plc (NYSE:STE) By 42%?Key Insights STERIS' estimated fair value is US$361 based on 2 Stage Free Cash Flow to Equity Current share price of... |
Reasons to Retain STE Stock in Your Portfolio NowSTERIS' strong prospects in the healthcare business bode well for investors. |
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
New Alliances to Support STERIS Stock Despite Macro IssuesSTE expects bioprocessing revenues to grow in the second half of fiscal 2025. |
Why Steris (STE) International Revenue Trends Deserve Your AttentionExamine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. |
Steris PLC (STE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Margin PressuresSteris PLC (STE) reports a 7% revenue increase and a 15% rise in adjusted EPS, despite facing challenges in gross and EBIT margins. |
Decoding Steris PLC (STE): A Strategic SWOT InsightUnveiling the Financial and Strategic Position of Steris PLC |
Q2 2025 STERIS plc Earnings CallQ2 2025 STERIS plc Earnings Call |
STERIS Shares Slide 4% Despite Strong EPS Beat and Growth in Key SegmentsSTERIS Posts Solid Q2 EPS Growth, But Revenue Miss and Life Sciences Decline Sink Shares |